Hippo pathway
- 阻害剤の選択性比較
- 溶解度
| カタログ番号 | 製品カタログ | 溶解度(25°C) | ||
|---|---|---|---|---|
| 水 | DMSO | アルコール | ||
| S1786 | Verteporfin | <1 mg/mL | 100 mg/mL | <1 mg/mL |
| S8334 | XMU-MP-1 | <1 mg/mL | 83 mg/mL | <1 mg/mL |
| S8554 | Super-TDU | 100 mg/mL | -1 mg/mL | -1 mg/mL |
| S8164 | YAP-TEAD Inhibitor 1 (Peptide 17) | 100 mg/mL | -1 mg/mL | -1 mg/mL |
| S8661 | CA3 | <1 mg/mL | 97 mg/mL | <1 mg/mL |
- Hippo pathway阻害剤(5)
- 新Hippo pathway製品
| 製品コード | 製品説明 | 文献中Selleckの製品使用例 | お客様のフィードバック |
|---|---|---|---|
| S1786 |
VerteporfinVerteporfin is a small molecule that inhibits TEAD–YAP association and YAP-induced liver overgrowth. It is also a potent second-generation photosensitizing agent derived from porphyrin. |
Verteporfin treatment inhibits proliferation and induces apoptosis of Tsc1-null cells in vivo. Mice were administered i.p. with vehicle or verteporfin at a dose of 100 mg/kg every other day for 10 d before sacrifice. Mice were sacrificed at 6 wk of age. Three independent experiments were performed and mice in different treatments were pooled for analysis. Percentage of Ki67 and αSMA double-positive cells in α-SMA+ mesenchymal lesions in the indicated kidneys. Immunofluorescence staining and counting were performed on three sagittal sections from different kidney regions for each mouse.
|
|
| S8334 |
XMU-MP-1XMU-MP-1 is an inhibitor of MST1/2 with IC50 values of 71.1±12.9 nM and 38.1±6.9 nM against MST1 and MST2, respectively. |
||
| S8554 |
Super-TDUSuper-TDU is an inhibitory peptide targeting YAP-TEADs interaction. |
||
| S8164 |
YAP-TEAD Inhibitor 1 (Peptide 17)Peptide 17 is a YAP-TEAD protein-protein interaction inhibitor which has potential usage in treatment of YAP-involved cancers with IC50 of 25 nM. |
||
| S8661新 |
CA3CA3 has potent inhibitory effects on YAP1/Tead transcriptional activity and primarily targets YAP1 high and therapy-resistant esophageal adenocarcinoma cells endowed with CSC properties. |
